Építés alatt – nem éles oldal
Belépés
Leállítva2/3. fázis

Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.

A legfontosabb adatok

Ki végzi
Peking University
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Leállítva
Fázis
2/3. fázis
Résztvevők
18 fő vett részt
Kezdés
2021. dec. 24.
Befejezés
2025. okt. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • HAIC
  • TACE
  • FOLFOX
  • cTACE or DEB-TACE
  • Donafenib
A regiszteradat frissítve
2025. december 18.
Miért állt le
Difficult to enroll participants

Ki vehet részt

Életkor
18 év – 75 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 29 feltétel megnézéseKevesebb

Ki vehet részt

  • Subjects must volunteer to participate in the study, signed informed consent, and were able to comply with the program requirements of visits and related procedures
  • Age and gender: >18 years old and≤75 years old, both men and women
  • All subjects must have Hepatocellular Carcinoma confirmed by pathological or clinical diagnosis
  • Subjects are not suitable for radical resection or radical ablative therapy
  • BCLC B based on Barcelona Clinic Liver Cancer staging system, and the lesions in the liver exceed up to 7 criteria, the number of tumors + the maximum diameter of tumors > 7
  • Patients with viable and measurable target lesion per mRECIST
  • Patients who are expected to live more than 3 months
  • ECOG PS 0-1
  • Child-Pugh class A
  • Patients with laboratory values that meet the following criteria:; Hemoglobin≥90 g/L; Neutrophile granulocytes≥1.5×109/L; Platelet count≥75×109/L; Albumin≥30 g/L; Total serum bilirubin ≤ 2 times upper limits of normal; AST and ALT ≤ 5 times upper limits of normal; Serum creatinine ≤ 1.5 times upper limits of normal; Alkaline phosphatase ≤ 5 times upper limits of normal; Prothrombin time or international normalized ratio ≤ 1.5 times upper limits of normal, activated partial thromboplastin time (APTT) ≤ 1.5×ULN

Ki nem vehet részt

  • Clinically significant cardiovascular disease, including, but not limited to, acute myocardial infarction, severe/unstable angina or prior coronary artery bypass surgery, congestive heart failure (NYHA >2), poorly controlled arrhythmias or arrhythmias requiring pacemaker therapy, hypertension not controlled by medication (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg) within the past 6 months
  • History of malignant tumor, excluding the following cases:; Malignant tumor that was curatively treated more than 5 years prior to study entry and has not recurred since then; Successful radical resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder carcinoma, preinvasive cervix carcinoma, and other preinvasive cancers
  • Preexisting or history of hepatic encephalopathy, hepatorenal syndrome or liver transplantation
  • History of surgical excision or ablation within 4 weeks of the start of treatment
  • History of hepatic arterial infusion, more than twice TACE therapy, or history of TACE within 6 months of the start of treatment
  • History of systemic therapy, including but not limited to chemotherapy, targeted therapy, immunotherapy
  • History of thrombosis and/or embolism within 6 months of the start of treatment
  • Clinically severe gastrointestinal bleeding within 6 months of the start of treatment or any life-threatening bleeding events within 3 months of the start of treatment
  • Severe infections that are active or clinically poorly controlled
  • If accompanied by acute or chronic active hepatitis B, unless taking antiviral drugs
  • Other significant clinical and laboratory abnormalities, such as uncontrolled diabetes, chronic kidney disease, grade II or above peripheral neuropathy (CTCAE V5.0), and thyroid dysfunction, that may affect the safety evaluation
  • Fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma confirmed by histology or cytology
  • Diffuse tumor lesion
  • The lesions load in the liver exceeds 20, the number of tumors + the maximum diameter of tumors > 20
  • Vascular invasion or extrahepatic metastasis
  • Clinically uncontrolled ascites or pleural effusion
  • Female patients who are pregnant, lactating, possibly pregnant, or planning to become pregnant, and fertile female or male patient who is unwilling or unable to use effective contraception
  • Multiple branches of hepatic artery with severe variation
  • Any other subjects that the investigator considers ineligible

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study is to evaluate the safety and efficacy of the combination therapy with HAIC-TACE and donafenib compared to TACE plus donafenib in patients with BCLC B stage unresectable hepatocellular carcinoma (HCC) out of up-to-seven criteria.

A vizsgálat 2 csoportja

  • HAIC-TACE-Dona GroupA vizsgált kezelés

    200 mg of donafenib (consisting of two 100-mg tablets) twice daily combine with hepatic arterial infusion chemotherapy that consists of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. After 2-4 cycles of HAIC treatment, the sequential TACE therapy would be performed.

    Kezelés: HAIC, TACE, FOLFOX, cTACE or DEB-TACE és Donafenib

  • TACE-Dona GroupMár használt kezelés, összehasonlításként

    200 mg of donafenib (consisting of two 100-mg tablets) twice daily combine with cTACE or DEB-TACE that mixed with EPI.

    Kezelés: TACE, cTACE or DEB-TACE és Donafenib

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage Hepatocellular Carcinoma Out Up-to-seven: a Multi-center Randomized Controlled Trial.
A regiszteradat frissítve
2025. december 18.